- Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAME
- ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on 11 heavily pre-treated patients in Phase 1b dose expansion Cohort A with median duration of response not reached at a median follow-up time of 8.5 months at data cut-off; next update in 4Q 2023
- Bristol Myers Squibb exercised first opt-in into 2019 cell therapy collaboration ($15 million option fee received) and made a $35 million equity investment
- Cash and cash equivalents as well as other financial assets not including the recent equity investment by Bristol Myers Squibb amount to $377.7 million1 (€347.6) as of June 30, 2023; updated projected cash runway is late 2025
Tuebingen, Germany and Houston, TX, August 17, 2023 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended June 30, 2023.
“The interim clinical data update for IMA203 monotherapy demonstrated an encouraging initial objective response rate in a range of solid cancer indications including durable responses supporting fast-tracking IMA203 to patients, starting with high-need solid cancers such as checkpoint-refractory melanoma and uveal melanoma,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics. “Beyond our recent IMA203 updates, we are pleased to report that we closed the second quarter with a cash position funding operations into late 2025. With this revised runway, we anticipate reaching our most critical milestones including the initiation of registration-directed trials for IMA203, as well as delivering meaningful data to assess clinical proof of concept for both TCER® programs IMA401 and IMA402.”
Second Quarter 2023 and Subsequent Company Progress
ACTengine® IMA203: ACTengine® IMA203 TCR-T against PRAME is currently being evaluated in an ongoing Phase 1b dose expansion trial.
- As per the latest data cut-off of April 4, 2023, ACTengine® IMA203 TCR-T monotherapy Cohort A showed a 67% confirmed objective response rate (cORR) in an interim clinical update announced on May 2, 2023. The data covered 11 heavily pre-treated patients; the median duration of response was not reached at a median follow-up time of 8.5 months. Patients were infused with IMA203 TCR-T cells at dose level (DL) 4 or DL5 with a mean total infused dose of 3.67×109 TCR-T cells (range 1.30-8.84×109 TCR-T cells).
- Cohort A IMA203 monotherapy TCR-T treatment continues to show manageable tolerability with no high-grade CRS and no ICANS; all 11 patients experienced expected cytopenia (Grade 1-4) associated with lymphodepletion. 10 patients (91%) had a low to moderate (Grade 1-2) cytokine release syndrome (CRS), of which 5 patients (45%) had Grade 1, and 5 patients (45%) had Grade 2 CRS.
- Objective responses were observed independent of tumor type including checkpoint-refractory and BRAF inhibitor-refractory cutaneous melanoma, platinum-resistant ovarian cancer, uveal melanoma, head and neck cancer and synovial sarcoma. Longest duration of responses were observed in cutaneous and uveal melanoma with ongoing responses at 6, 9 and 10 months post infusion at data cut-off.
- IMA203 in combination with nivolumab (Cohort B) has been de-prioritized in the last-line setting. Such a combination is being considered for the front-line setting.
- IMA203CD8 (Cohort C) is a next-generation monotherapy where IMA203 engineered T cells are co-transduced with a CD8αβ co-receptor. IMA203CD8 is currently being explored in DL4a (up to 0.8×109 TCR-T cells/m2 BSA).
- Next update on Immatics’ IMA203 Phase 1b cohorts, including the projected clinical development path for PRAME-targeted TCR-T monotherapy towards registration-directed trials is planned for 4Q 2023. Immatics’ IMA203 development strategy to realize the multi-cancer opportunity of targeting PRAME is based on two pillars aimed at:
- maximizing speed to market in one to two last-line solid cancer types focusing on cutaneous melanoma, uveal melanoma and potentially other tumor types with high PRAME prevalence where clinical proof-of-concept has been demonstrated, and
- broad development with expansion to other cancer types, such as ovarian cancer, uterine cancer, lung cancer, breast cancer, head and neck cancer and other tumor types having a broad patient reach.
- Earlier this year, Bristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most advanced TCR-T product candidate. As part of the agreement, Immatics received an option payment of $15 million and is eligible for up to $490 million in milestone payments in addition to tiered royalties on net sales of the product.
Immatics’ T cell engaging receptor (TCER®) candidates are next-generation, half-life extended TCR Bispecific molecules designed to maximize efficacy while minimizing toxicities in patients through Immatics’ proprietary format using a low-affinity T cell recruiter and a high-affinity TCR domain.
- TCER® IMA401 (MAGEA4/8) – Phase 1 trial to evaluate safety, tolerability and initial anti-tumor activity of TCER® IMA401 in patients with recurrent and/or refractory solid tumors is ongoing. IMA401 targets an HLA-A*02:01-presented peptide that occurs identically in two different proteins, MAGEA4 and MAGEA8. This target peptide has been selected based on natural expression in native solid tumors at particularly high target density (peptide copy number per tumor cell identified by Immatics’ proprietary quantitative mass spectrometry engine XPRESIDENT®). MAGEA4 and MAGEA8 are expressed in multiple solid cancers including lung cancer, head and neck cancer, melanoma, ovarian cancer, sarcoma and others. IMA401 is being developed in collaboration with Bristol Myers Squibb.
- TCER® IMA402 (PRAME) – Immatics submitted a clinical trial application (CTA2) to the Paul-Ehrlich-Institute (PEI) in April 2023. Following CTA acceptance, Immatics initiated the Phase 1/2 trial investigating the company’s fully owned TCER® candidate IMA402 in patients with recurrent and/or refractory solid tumors in August. Initial focus indications are cutaneous and uveal melanoma, ovarian cancer, lung cancer, uterine cancer and synovial sarcoma, among others. A first clinical data update is planned for 2024. IMA402 targets an HLA-A*02:01-presented peptide derived from the tumor antigen PRAME. This target peptide has been selected based on natural expression in native solid primary tumors and metastases at particularly high target density (peptide copy number per tumor cell identified by Immatics’ proprietary quantitative mass spectrometry engine XPRESIDENT®).
- On July 24, 2023, Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price per share of $14.463. Additionally, Bristol Myers Squibb will appoint a member to the Immatics Scientific Advisory Board.
Second Quarter 2023 Financial Results
Equity: The Company raised a total of $64 million in June through August through its ATM facility.
Cash Position: Cash and cash equivalents as well as other financial assets total €347.6 million ($377.7 million1) as of June 30, 2023, compared to €362.2 million ($393.6 million1) as of December 31, 2022. The decrease is mainly due to our ongoing research and development activities, partially offset by the option fee received by Bristol Myers Squibb and funds raised in the period. The Company projects an updated cash runway into late 2025.
Revenue: Total revenue, consisting of revenue from collaboration agreements, was €22.4 million ($24.3 million1) for the three months ended June 30, 2023, compared to €17.2 million ($18.7 million1) for the three months ended June 30, 2022. The increase is mainly related to the recognition of revenue for the opt-in agreement with Bristol Myers Squibb signed during the three months ended June 30, 2023.
Research and Development Expenses: R&D expenses were €27.3 million ($29.7 million1) for the three months ended June 30, 2023, compared to €25.2 million ($27.4 million1) for the three months ended June 30, 2022. The increase mainly resulted from higher costs associated with the advancement of the clinical and pre-IND pipeline of ACTengine® and TCER® candidates.
General and Administrative Expenses: G&A expenses were €9.4 million ($10.2 million1) for the three months ended June 30, 2023, compared to €8.7 million ($9.5 million1) for the three months ended June 30, 2022.
Net Profit and Loss: Net loss was €24.6 million ($26.7 million1) for the three months ended June 30, 2023, compared to a net loss of €14.0 million ($15.2 million1) for the three months ended June 30, 2022. The increased net loss mainly resulted from non-cash fair value adjustments of outstanding warrants.
Upcoming Investor Conferences
- Jefferies Cell & Genetic Medicine Summit, New York, NY – September 26-27, 2023
- Jefferies London Healthcare Conference, London, U.K. – November 14-16, 2023
To see the full list of events and presentations, visit https://investors.immatics.com/events-presentations.
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics’ future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics’ focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including general economic conditions and other risks, uncertainties and factors set forth in filings with the SEC. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.
For more information, please contact:
|Media and Investor Relations Contact|
|Eva Mulder or Charlotte Spitz|
|Phone: +31 6 52 33 15 79|
|Anja Heuer||Sabrina Schecher, Ph.D.|
|Senior Director, Corporate Communications||Senior Director, Investor Relations|
|Phone: +49 89 540415-606||Phone: +49 89 262002433|
|[email protected]||[email protected]|
Unaudited Condensed Consolidated Statement of Profit/(Loss) of Immatics N.V.
| Three months ended June 30,
| Six months ended June 30,
| (Euros in thousands, except
per share data)
| (Euros in thousands, except
per share data)
|Revenue from collaboration agreements||22,354||17,215||32,150||120,123|
|Research and development expenses||(27,317)||(25,216)||(54,898)||(50,360)|
|General and administrative expenses||(9,358)||(8,683)||(18,944)||(17,961)|
|Change in fair value of liabilities for warrants||(13,105)||(2,786)||(5,708)||13,743|
|Other financial income||3,954||7,015||6,748||8,774|
|Other financial expenses||(1,144)||(407)||(4,653)||(1,524)|
|Profit/(loss) before taxes||(24,610)||(12,835)||(44,357)||72,827|
|Taxes on income||—||(1,145)||—||(1,145)|
|Net profit/(loss) per share:|
Unaudited Condensed Consolidated Statement of Comprehensive Income/(Loss) of Immatics N.V.
| Three months ended June 30,
| Six months ended June 30,
|(Euros in thousands)||(Euros in thousands)|
|Other comprehensive income/(loss)|
|Items that may be reclassified subsequently to profit or loss|
|Currency translation differences from foreign operations||(224)||778||340||1,338|
|Total comprehensive income/(loss) for the year||(24,834)||(13,202)||(44,017)||73,020|
Unaudited Condensed Consolidated Statement of Financial Position of Immatics N.V.
| As of
| June 30,
| December 31,
|(Euros in thousands)|
|Cash and cash equivalents||130,405||148,519|
|Other financial assets||217,222||213,686|
|Other current assets||16,668||13,838|
|Total current assets||364,625||377,154|
|Property, plant and equipment||27,188||13,456|
|Other non-current assets||1,972||2,545|
|Total non-current assets||45,564||30,666|
|Liabilities and shareholders’ equity|
|Liabilities for warrants||22,622||16,914|
|Other current liabilities||7,929||9,366|
|Total current liabilities||124,306||106,452|
|Other non-current liabilities||26||42|
|Total non-current liabilities||67,670||88,204|
|Total shareholders’ equity||218,213||213,164|
|Total liabilities and shareholders’ equity||410,189||407,820|
Unaudited Condensed Consolidated Statement of Cash Flows of Immatics N.V.
| Six months ended June 30,
|(Euros in thousands)|
|Cash flows from operating activities|
|Taxes on income||—||1,145|
|Profit/(loss) before tax||(44,357)||72,827|
|Depreciation and amortization||3,666||3,407|
|Equity settled share-based payment||11,615||11,262|
|Net foreign exchange differences and expected credit losses||4,081||(7,834)|
|Change in fair value of liabilities for warrants||5,708||(13,743)|
|Decrease/(increase) in accounts receivables||781||(280)|
|Decrease/(increase) in other assets||765||(6,903)|
|(Decrease)/increase in deferred revenue, accounts payables and other liabilities||(9,889)||96,933|
|Income tax paid||—||—|
|Net cash (used in)/provided by operating activities||(30,323)||155,773|
|Cash flows from investing activities|
|Payments for property, plant and equipment||(15,004)||(1,965)|
|Payments for intangible assets||(154)||(6)|
|Proceeds from disposal of property, plant and equipment||—||1|
|Payments for investments classified in Other financial assets||(170,326)||(59,253)|
|Proceeds from maturity of investments classified in Other financial assets||164,929||12,695|
|Net cash (used in)/provided by investing activities||(20,555)||(48,528)|
|Cash flows from financing activities|
|Proceeds from issuance of shares to equity holders||38,608||17,112|
|Transaction costs deducted from equity||(1,157)||(515)|
|Repayment of lease liabilities||(1,866)||(1,394)|
|Net cash provided by/(used in) financing activities||35,585||15,203|
|Net (decrease)/increase in cash and cash equivalents||(15,293)||122,448|
|Cash and cash equivalents at beginning of the year||148,519||132,994|
|Effects of exchange rate changes and expected credit losses on cash and cash equivalents||(2,821)||9,683|
|Cash and cash equivalents at end of the year||130,405||265,125|
Unaudited Condensed Consolidated Statement of Changes in Shareholders’ equity of Immatics N.V.
| (Euros in thousands)
|Balance as of January 1, 2022||629||565,192||(537,813)||(3,945)||24,063|
|Other comprehensive income||—||—||—||1,338||1,338|
|Comprehensive income for the year||—||—||71,682||1,338||73,020|
|Equity-settled share-based compensation||—||11,262||—||—||11,262|
|Share options exercised||—||1||—||—||1|
|Issue of share capital – net of transaction costs||24||16,571||—||—||16,595|
|Balance as of June 30, 2022||653||593,026||(466,131)||(2,607)||124,941|
|Balance as of January 1, 2023||767||714,177||(500,299)||(1,481)||213,164|
|Other comprehensive income||—||—||—||340||340|
|Comprehensive loss for the year||—||—||(44,357)||340||(44,017)|
|Equity-settled share-based compensation||—||11,615||—||—||11,615|
|Share options exercised||—||40||—||—||40|
|Issue of share capital – net of transaction costs||37||37,374||—||—||37,411|
|Balance as of June 30, 2023||804||763,206||(544,656)||(1,141)||218,213|
1 All amounts translated using the exchange rate published by the European Central Bank in effect as of June 30, 2023 (1 EUR = 1.0866 USD).
2 Clinical Trial Application (CTA) is the European equivalent of an Investigational New Drug (IND) application.
3 Exact price per share $14.4639.